Last update Aug. 30, 2021
Synthetic progestogen structurally related to progesterone and without estrogenic or androgenic properties. It does not cause virilization (BNF 2018-2019 p478).
Indicated in the treatment of menorrgesteronehagia, endometriosis, threatening spontaneous abortion and recurrent spontaneous abortion and in cases of infertility.
Oral administration, once or twice a day.
At the date of the last update, there was no available published data on its excretion in breast milk.
Its pharmacokinetic data (large volume of distribution and high percentage of protein binding) make it unlikely that significant amounts will be transferred to breast milk.
Other similar progestogens are excreted in negligible amounts in breast milk (HPFA 2017, Abbot 2014).
Its low oral bioavailability make it difficult for the infant to pass into plasma from ingested breast milk, except in premature infants and during the immediate neonatal period during which there may be greater intestinal permeability.
We do not have alternatives for G03DB01.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM